Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shilpa Medicare Limited ( (IN:SHILPAMED) ) has issued an announcement.
Shilpa Medicare Limited has received approval from the National Company Law Tribunal’s Bengaluru Bench for the amalgamation of its wholly owned subsidiary, Shilpa Therapeutics Private Limited, with the parent company. The tribunal sanctioned the scheme of amalgamation under the Companies Act, 2013, through an order dated 27 February 2026, which has been made available on the NCLT website.
The merger will become effective once certified copies of the NCLT order are obtained and filed with the Registrar of Companies, along with fulfilment of other conditions specified in the scheme. The consolidation is expected to simplify the corporate structure by integrating the subsidiary into Shilpa Medicare, which may enhance operational efficiency and provide greater transparency for shareholders and regulators.
More about Shilpa Medicare Limited
Shilpa Medicare Limited is an India-based pharmaceutical company operating in the healthcare sector, with corporate and administrative offices in Raichur, Karnataka. The company focuses on developing and manufacturing therapeutic products, and operates through subsidiaries such as Shilpa Therapeutics Private Limited to expand its offerings and streamline its business structure.
Average Trading Volume: 15,201
Technical Sentiment Signal: Hold
Current Market Cap: 63.3B INR
Find detailed analytics on SHILPAMED stock on TipRanks’ Stock Analysis page.